ライフサイエンスコーパス: adenovirus

1 ction of PBCV-1, which is similar to that of adenovirus.

2 co-administered with the antigen-expressing adenovirus.

3 ition, we show inhibition of a non-enveloped adenovirus.

4 y increased when ILF3 is overexpressed using adenovirus.

5 virus, sapovirus, astrovirus, rotavirus, and adenovirus.

6 are increased when ILF3 is overexpressed by adenovirus.

7 s, some archaeal viruses, herpesviruses, and adenoviruses.

8 l assembly, especially for herpesviruses and adenoviruses.

9 cipients for several human herpesviruses and adenoviruses.

10 Discordance was common for adenovirus (100%), metapneumovirus (44%), rhinovirus (34

11 We used replication-competent adenovirus 11 (Ad11pGFP) and adenovirus 5 containing ade

12 ic peptides identical or very similar to the adenovirus 12 E1A spacer region were determined and foun

13 g pathways activated during infection, while adenovirus 12 E4orf6 negates Chk1 activation by promotin

14 Ad155-RSV) using the viral vector chimpanzee-adenovirus-155, encoding RSV fusion (F), nucleocapsid, a

15 further randomly assigned at a 5:1 ratio to adenovirus 26 (Ad26)-vectored vaccine and placebo subgro

16 ne, Ad26.RSV.preF, a replication-incompetent adenovirus 26 vector encoding the F protein stabilized i

17 us 11 (Ad11pGFP) and adenovirus 5 containing adenovirus 35 fiber (Ad5F35GFP) viruses and T cells spec

18 Prior infection with adenovirus 36 (Adv36) has been associated with increased

19 mologous respiratory challenge observed with adenovirus 4 and 7 vaccines.

20 Since the 1970s, replication-competent human adenoviruses 4 and 7 have been used as oral vaccines to

21 ; icddr,b AF 39.9%; 38.0, 41.8), followed by adenovirus 40/41 (Nationwide AF 17.9%, CI: 13.9, 21.9; i

22 Adenovirus 40/41 was the second leading pathogen in both

23 protection was observed for other bacteria, adenovirus 40/41, and sapovirus.

24 Rotavirus, adenovirus 40/41, and V. cholerae were the leading etiol

25 even among vaccinated children, followed by adenovirus 40/41, Shigella/enteroinvasive Escherichia co

26 7%]; sapovirus: -9% [95%CI, -3 to -15%]; and adenovirus 40/41: -9% [95%CI, -2 to - 15%]).

27 of virus tropism, but not hepatitis C virus, adenovirus 5 (ADV5), Zika virus, and influenza (H1N1) vi

28 phase 2b efficacy trial of a DNA/recombinant adenovirus 5 (rAd5) HIV vaccine regimen.

29 HVTN 505 efficacy trial of a DNA/recombinant adenovirus 5 (rAd5) vaccine regimen, we found that host

30 ended and optimized our previous recombinant adenovirus 5 (rAd5)-based vaccine platform characterized

31 ation-competent adenovirus 11 (Ad11pGFP) and adenovirus 5 containing adenovirus 35 fiber (Ad5F35GFP)

32 achinery through transient expression of the adenovirus 5 E4orf6/7 protein, which recruits the cell-c

33 rpes simplex virus 1, and nonenveloped human adenovirus 5.

34 These findings suggest that adenovirus 7 infection alone can result in HLH.

35 The adenovirus (Ad) E4orf4 protein contributes to virus-indu

36 We have previously shown that the adenovirus (Ad) E4orf4 protein inhibits DDR signaling, b

37 We present a novel mechanism by which the adenovirus (Ad) E4orf4 protein inhibits the DDR.

38 The adenovirus (Ad) E4orf4 protein was reported to contribut

39 Here, we describe a method for cloaking adenovirus (Ad) in silica (SiAd) as a nanoparticle formu

40 Here, we show that adenovirus (Ad) vector-based ZIKV vaccines induce potent

41 rsion AdrA mutant (mut) were delivered by an adenovirus (Ad) vector.

42 onchoalveolar lavage (BAL) following mucosal adenovirus (Ad)-SIV recombinant priming, intramuscular S

43 d following mucosal priming with replicating adenovirus (Ad)-SIV recombinants, systemic boosting with

44 t mice were then administered Cre-expressing adenovirus (Ad-Cre) to inactivate Tgfbr2 in transplanted

45 red through a replication incompetent type 5 adenovirus (Ad.mda-7) or with His-MDA-7/IL-24 protein, d

46 y of human ACE2 with a replication-deficient adenovirus (Ad5-hACE2).

47 More than 80 different adenovirus (AdV) types infect humans through the respira

48 We report on predictors of adenovirus (ADV) viremia and correlation of ADV viral ki

49 n haploid cells to identify host factors for adenovirus (AdV), a DNA virus that can cause severe resp

50 echanism supporting the persistence of human adenovirus (AdV), a virus that can kill immunosuppressed

51 a virus (PIV), human metapneumovirus (HMPV), adenovirus (AdV), rhinovirus (RV), bocavirus (BoV), and

52 Adenoviruses (AdV) have been associated with a variety o

53 related double-stranded DNA (dsDNA) viruses (adenovirus [ADV], BK virus [BKV], cytomegalovirus [CMV],

54 ur understanding of the relationship between adenovirus and DNA damage and cell cycle signaling pathw

55 In this comprehensive evaluation, adenovirus and HHV-6 were associated with intussusceptio

56 4-Cre;Wnt10a(flox/flox) molars by Wnt4 shRNA adenovirus and kidney capsule grafts, the root furcation

57 tion with dual-antigen vectors, using simian adenovirus and modified vaccinia virus Ankara vectors.

58 , we modeled the inactivation of three-human adenovirus and two bacteriophages-MS2 and phiX174-in sur

59 s for immediate screening of novel oncolytic adenoviruses and selection of optimal viral genome alter

60 oorly permissive cancer cells with wild-type adenoviruses and the oncolytic chimeric adenovirus enade

61 anded DNA (dsDNA) phages, herpesviruses, and adenoviruses and, as such, is a viable antiviral therape

62 ycoplasma genitalium, Trichomonas vaginalis, adenovirus, and herpes simplex virus were absent.

63 Immunohistochemistry for cytomegalovirus, adenovirus, and simian virus 40 were negative.

64 ll the human polyomaviruses BK/JC/MCV, human adenoviruses, and human papillomaviruses.

65 in the body.IMPORTANCE Replication-competent adenoviruses appear to be promising vectors for the deve

66 regimens, using either dendritic cells or an adenovirus approach targeting nuclear antigen EBNA1 foll

67 Adenoviruses are a major cause of infectious mortality i

68 cogenic, whereas most of the remaining human adenoviruses are nononcogenic.

69 Adenoviruses are responsible for a spectrum of pathogene

70 Group B adenoviruses are weakly oncogenic, whereas most of the r

71 In this study, we explored adenovirus as a platform for corrective CRISPR/Cas9-medi

72 Given the safety record of adenovirus as vaccine or delivery vectors, this approach

73 ovel in vivo proxy sensor of KOR activation, adenovirus associated double floxed inverted-HyPerRed, a

74 ed in hepatitis B virus (HBV)-transgenic and adenovirus-associated virus (AAV)-HBV mouse models.

75 ured with autologous monocytes infected with adenovirus at low multiplicity of infection.

76 Adenovirus based vectors are of increasing importance fo

77 be used to improve the treatment outcome of adenovirus-based cancer immunotherapy.

78 to modify the immune responses induced by an adenovirus-based vaccine.

79 of MAV-1 to study replication-competent oral adenovirus-based vaccines but also highlight the fact th

80 in mice to study oral replication-competent adenovirus-based vaccines.

81 CD141+ DCs 1 day after immunization with the adenovirus-based vaccines.

82 turing and vaccination strategies.IMPORTANCE Adenovirus-based vectors are used today for gene transfe

83 on spectrum of PBCV-1 was similar to that of adenovirus between 214 and 289 nm.

84 vestigate delivery of both the BCG prime and adenovirus boost vaccination via the airway in a murine

85 articular, the heterologous EBNA1-expressing adenovirus, boosted by EBNA1-encoding MVA vaccination, d

86 adeno-associated virus serotype 9 (in vivo), adenovirus (both in vivo and in vitro), and small interf

87 reveal that complement component C4 inhibits adenovirus by inactivating the virus capsid through mech

88 Adenovirus C detection <20 quantification cycles was ass

89 show that systemic delivery of R-spondin via adenovirus can promote generation of differentiated tast

90 bling and cell-penetrating activities of the adenovirus capsid penton base.

91 the loss of ZO-1, Connexin-45 and Coxsackie-adenovirus (CAR) proteins were reduced in atria of ZO-1c

92 All adenoviruses caused an increase in glucose and glutamine

93 In the first, antibody binding of adenovirus causes lysosomal damage, activating NLRP3 to

94 PV3 was delivered by plasmid DNA, chimpanzee adenovirus (ChAdOx1) and modified vaccinia Ankara (MVA)

95 Simian adenovirus (ChAdOx1) encoding a genetic immune enhancer

96 RAd technology that consists of an oncolytic adenovirus coated with MHC-I-restricted tumor-specific p

97 l during viral infection using a recombinant adenovirus coding for a mitochondrial tracer protein for

98 n, it has recently been shown that the major adenovirus condensing protein (polypeptide VII) is dispe

99 s (HUVECs) and SC cells were transduced with adenovirus containing eNOS promoter driving secreted alk

100 Using engineered adenoviruses containing a functional fragment of the she

101 The pathogens identified are adenovirus, coronavirus 229E, coronavirus HKU1, coronavi

102 protected against subsequent infection with adenovirus, coronavirus, enterovirus/rhinovirus, and inf

103 The data showed that adenovirus delivery of LOXL2 upregulated LOXL2 and aggre

104 t mice, expression of L-OPA1Delta by in vivo adenovirus delivery restored the morphology but not the

105 ated the mechanisms of LOAd713, an oncolytic adenovirus designed to block IL-6R signaling and to prov

106 Adenovirus differentially regulates ATR DNA damage respo

107 of BALB/cByJ mice with tcMCMV or recombinant adenoviruses differentially activates T helper (T(h))1,

108 e from multiple HLA-A*01(+) donors prevented adenovirus dissemination, and nonstimulated T cells did

109 ulation of hepatic GRK2 during fasting using adenovirus-driven overexpression of this kinase in the l

110 MARCAL1 was found associated with E1B-55K in adenovirus E1-transformed cells.

111 with expression of other oncogenes, such as adenovirus E1A or MYC, HPV16 E7-expressing cells are sen

112 (forkhead box O3a)-BNIP3 (B-cell lymphoma 2/adenovirus E1B 19kDa interacting protein 3) pathway modu

113 The cellular adenovirus E1B-55K binding protein E1B-AP5 participates

114 ides equivalent to a region within the human adenovirus early region 1A protein that confers, in part

115 AN, and other anabolic genes compared to the adenovirus-Empty-treated implants.

116 type adenoviruses and the oncolytic chimeric adenovirus enadenotucirev (EnAd).

117 Adenovirus encodes two early proteins, E1B55K and E4orf6

118 le hydrogel encapsulation for delivery of an adenovirus encoding Flagrp170 (Adv-Flagrp170), which has

119 irst report that delivery of rapamycin or an adenovirus encoding the dominant negative acting mTOR-mu

120 Here, we transduced replication-defective adenoviruses encoding human ACE2 via intranasal administ

121 Delta-24-RGD is a replication competent adenovirus engineered to replicate in tumor cells with a

122 rdiomyocytes transduced with RFFL-expressing adenovirus exhibited reduced total expression of the pot

123 cells may provide insight into how oncolytic adenoviruses exploit metabolic transformation to augment

124 Adult rabbit cardiomyocytes with adenovirus-expressed RFFL exhibited reduced rapid delaye

125 Human adenovirus expresses several early proteins that control

126 ther virus with retrograde tropism, a canine adenovirus expressing Cre recombinase, was injected into

127 m Atf6alpha (flox/flox) mice transduced with adenovirus expressing Cre recombinase.

128 ne comprising a replication-deficient simian adenovirus expressing full-length SARS-CoV-2 spike prote

129 Intravenous administration of a recombinant adenovirus expressing wild-type human ABCC6 in Abcc6(-/-

130 to alter CaM function by directly injecting adenoviruses expressing CaM-wild type, a loss-of-functio

131 entricular cardiomyocytes were infected with adenoviruses expressing either wild-type CryAB (CryAB(WT

132 egalovirus (tcMCMV) or replication-deficient adenoviruses expressing individual murine cytomegaloviru

133 an DCs isolated from HIS mice immunized with adenoviruses expressing malaria/human immunodeficiency v

134 Third, it uses adenovirus for the capacity to package the all-in-one ve

135 eed to identify nonpathogenic surrogates for adenovirus for the water treatment industry.

136 d safety of a new low-seroprevalence gorilla adenovirus (GAd; GC46) as a gene transfer vector in mice

137 receptor TRIM21 to block transduction by an adenovirus gene therapy vector but is partially restored

138 ults indicate that protein VII condenses the adenovirus genome by combining direct clustering and pro

139 pment shared 100% identity across the entire adenovirus genome.

140 Attachment of human adenovirus (HAd) to the host cell is a critical step of

141 The effective treatment of adenovirus (HAdV) infections in immunocompromised patien

142 An effective therapy for human adenovirus (HAdV) infections in immunocompromised patien

143 ally intriguing and predicted emergent human adenovirus (HAdV) pathogen, which caused pneumonia and d

144 o characterize the etiological role of human adenovirus (HAdV) serotypes in pediatric gastroenteritis

145 om 10 of 14 patients were positive for human adenovirus (HAdV) while swabs from 2 of 14 patients were

146 Human adenoviruses (HAdV) are ubiquitous within the human popu

147 has long been established that group A human adenoviruses (HAdV-A12, -A18, and -A31) can cause tumors

148 Human adenoviruses (HAdVs) are being explored as vectors for g

149 ta1-mediated nuclear import.IMPORTANCE Human adenoviruses (HAdVs) represent a ubiquitous and clinical

150 Adenovirus has been associated with intussusception and

151 Adenovirus has evolved, primarily, to inhibit DNA damage

152 Adenoviruses have been associated with HLH but molecular

153 Human adenoviruses have many attractive features for gene ther

154 These data establish that engineered adenoviruses have the capacity to quantify and localize

155 Prior infection with adenovirus (hazard ratio [HR], 0.24; 95% confidence inte

156 In addition, the most commonly used human adenovirus, human adenovirus subgroup C serotype 5 (HAd5

157 Cases were defined as hospital-acquired adenovirus identified from any clinical specimen (NICU p

158 Adenovirus immune complexes with the engineered Fc induc

159 useful model to study the pathogenesis of an adenovirus in its natural host.

160 Outbreaks of adenovirus in neonatal intensive care units (NICUs) can

161 etabolism induced by oncolytic and wild-type adenoviruses in cancer cells, which will be important to

162 strated good therapeutic index for oncolytic adenoviruses in patients with solid tumours when adminis

163 4.7% of cases and 1.5% of controls), enteric adenovirus (in 29.1% and 2.7%, respectively), Cryptospor

164 Co-expression of TRAM and an antigen from adenoviruses increased the transgene-specific CD8+ T cel

165 iruses such as vaccinia, herpes simplex, and adenovirus induced increased IFN production, which resul

166 angstrom(2)) and heterogeneous objects in an Adenovirus-infected cell over large fields of view (1.14

167 ed to viral replication centers early during adenovirus infection and is then targeted in an E1B-55K/

168 overlap between the metabolic phenotypes of adenovirus infection and transformed tumor cells may pro

169 C4 inhibits human adenovirus infection by directly inactivating the virus

170 characteristics of 5 children admitted with adenovirus infection during 2018-2019 who developed HLH

171 o treat maternally-transmitted, disseminated adenovirus infection in a premature infant.

172 These data shed new light on adenovirus infection strategies and provide insights for

173 e system can instruct the innate response to adenovirus infection.

174 f neonates undergoing examinations developed adenovirus infection.

175 We identified the seasonality of rhinovirus, adenovirus, influenza A and B viruses, human parainfluen

176 Following logistic regression adenovirus, influenza viruses A, B, RSV and HMPV preferr

177 In addition, adenovirus injection every 4 weeks restored plasma pyrop

178 transients in ventricular myocytes near the adenovirus-injection sites in Langendorff-perfused intac

179 Adenovirus is a nuclear replicating DNA virus reliant on

180 Adenovirus is among the most UV-resistant waterborne hum

181 Adenovirus isolates were recovered from 4/5 cases; all w

182 viruses, eight human enteric viruses [human adenoviruses, JC and BK polyomaviruses, Aichi virus 1 (A

183 eral injection of Mgp.floxed mice with a Cre-adenovirus, led to an Mgp.TMcKO mouse which developed el

184 in 35 custom destination vectors, including adenovirus, lentivirus, PiggyBac transposon, and Sleepin

185 fied Jothikumar assay both consistently gave adenovirus levels lower than the commercial platform for

186 Adenovirus LOXL2 -treated implants showed higher mRNA le

187 after inoculation with replication-deficient adenoviruses, lymphocytes from the submandibular gland e

188 in receptor knockout [L-IRKO] + GFP), before adenovirus-mediated add back of wild-type (WT) or mutant

189 cated by upregulating TIE2 signaling through adenovirus-mediated angiopoietin-1 (Angpt1) gene therapy

190 We find that adenovirus-mediated C/EBPgamma expression in the lung ti

191 o insulin resistance in macrophages, whereas adenovirus-mediated expression of IL-10 ameliorates post

192 Augmenting tissue GLO1 expression by adenovirus-mediated gene transfer or with the small-mole

193 d increased apoptosis, which were rescued by adenovirus-mediated GLO1 overexpression.

194 In this study, using adenovirus-mediated overexpression of a tagged EMCN in h

195 Specifically, adenovirus-mediated overexpression of HIPK2 suppressed t

196 Adenovirus-mediated overexpression of inhibitor of DNA b

197 In vitro, adenovirus-mediated overexpression of Tsg101 in neonatal

198 Adenovirus-mediated re-expression of HuR in hepatocytes

199 Adenovirus minor coat protein VI contains a membrane-dis

200 Adenovirus mutants lacking E1B55K or E4orf6 display defe

201 .IMPORTANCE To successfully replicate, human adenovirus needs to carry out a rapid yet ordered transc

202 Oncolytic adenovirus (oAd)-mediated gene therapy is a promising ap

203 Prior adenovirus or influenza virus infection conferred cross-

204 9-based mouse model of SCLC by delivering an adenovirus (or an adeno-associated virus [AAV]) that exp

205 Adenovirus (OR, 2.67; 95% CI, 1.75-4.36) and human herpe

206 produced in mice what is observed with human adenovirus oral vaccines, it also highlighted that oral

207 , response, and successful containment of an adenovirus outbreak in a NICU associated with contaminat

208 Adenovirus outbreaks can result from use of contaminated

209 evels in the brains of male db/db mice using adenovirus overexpressing Cav-1 (AAV-Cav-1) rescues lear

210 all interfering RNA (siRNA) transfection and adenovirus overexpression were used.

211 protected against subsequent infection with adenovirus (P = .044) and influenza virus (P = .081).

212 A (dsDNA) bacteriophages, herpesviruses, and adenoviruses package their genetic material into a precu

213 re, we study the morphology and mechanics of adenovirus particles with (Ad5-wt) and without (Ad5-VII-

214 Overall, our findings show that the adenovirus platform is suitable for gene insertion in ju

215 Adenovirus-positive participants with FRI episodes tende

216 Replication-defective adenovirus (rAd) vaccine vectors are at the forefront of

217 ious studies employing replication-defective adenovirus (rAd) vectors that transiently express SIV in

218 tumor microenvironment as well as decreased adenovirus-reactive antibodies.

219 lls, which identified the coxsackievirus and adenovirus receptor (CAR) as a candidate ReCV entry rece

220 ntified and validated the coxsackievirus and adenovirus receptor (CAR) as a functional proteinaceous

221 stigated the roles of the coxsackievirus and adenovirus receptor (CAR), CD46, and alphav integrins in

222 attachment receptors, CD46 and Coxsackie and Adenovirus Receptor (CAR).

223 strongly express cell-surface coxsackie and adenovirus receptor (CXADR) genes, which can facilitate

224 The coxsackie and adenovirus receptor (CXADR), a TJ protein with an essent

225 we hypothesized that the coxsackievirus and adenovirus receptor (CXADR/CAR), although absent in norm

226 concentrations of soluble coxsackievirus and adenovirus receptor (sCAR) were similar with and without

227 n engineered sCAR-Fc (soluble coxsackievirus-adenovirus receptor fused to the carboxyl-terminus of hu

228 deaths from AEs, influenza/aspergillosis and adenovirus-related hepatitis.

229 virus, sapovirus, astrovirus, rotavirus, and adenovirus, respectively.

230 virus, sapovirus, astrovirus, rotavirus, and adenovirus, respectively.

231 were immunized with replicating single-cycle adenovirus (SC-Ad) vaccines expressing clade B HIV-1 gp1

232 and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expr

233 A single immunization with an adenovirus serotype 26 vector-based vaccine expressing a

234 nses and 2 indirect ophthalmoscopes revealed adenovirus serotype 3 DNA on each device.

235 We show that adenovirus serotype 5 (Ad5) bio-distributes at very low

236 cy trial testing DNA followed by recombinant adenovirus serotype 5 (rAd5) in circumcised, Ad5-seroneg

237 under increased scrutiny, since trials with adenovirus serotype 5-vectored (Ad5-vectored) HIV vaccin

238 The extent of alpha-helix in E1A from other adenovirus species can be correlated to a limited degree

239 As vaccines, vectors derived from human adenovirus species D serotypes 26 and 48 (HAdV-D26/48) a

240 post-transplant care, and early transfer of adenovirus-specific donor T cells during aplasia resulte

241 method to measure the antiviral capacity of adenovirus-specific T cell responses.

242 l transplantation, with adoptive transfer of adenovirus-specific T cells being an effective therapeut

243 e most commonly used human adenovirus, human adenovirus subgroup C serotype 5 (HAd5), when systemical

244 , PBCV-1 appears to represent an appropriate adenovirus surrogate for UV system performance evaluatio

245 cium bursaria chlorella virus (PBCV-1) as an adenovirus surrogate for validation of UV reactors was e

246 Therefore, we propose that adenovirus targets SMARCAL1 for degradation during infec

247 Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA i

248 e identity with two recently isolated simian adenoviruses that contain cross-species genome recombina

249 t are most efficiently primed by recombinant adenoviruses that encode EBNA1.

250 ude cytomegalovirus, Epstein-Barr virus, and adenovirus, though recent published studies have success

251 Entrapment and binding of adenovirus to erythrocytes, blood factors, and neutralis

252 fectious cycling in the presence of a helper adenovirus to yield a new AAV variant that then serves a

253 However, the inability of human adenoviruses to replicate efficiently in laboratory anim

254 After delivering adenoviruses to the SC lumen by retroperfusion, the flow

255 Since the complex adenovirus transcriptome includes overlapping spliced un

256 sequencing, here we profile m(6)A within the adenovirus transcriptome using a combination of meRIP-se

257 sion, and re-expressing the ET(B)R gene with adenovirus transduction, and determine the treatment eff

258 g RNA and small hairpin RNA interference and adenovirus transfection were adopted to manipulate the e

259 Adenovirus transformed cells have a dedifferentiated phe

260 In human macrophages, antibody-coated adenovirus triggers a novel TRIM21-dependent pathway tha

261 Here, we used mouse adenovirus type 1 (MAV-1) in mice to study oral replicat

262 Acute respiratory infection with mouse adenovirus type 1 (MAV-1) induces activity of the immuno

263 In this study, mouse adenovirus type 1 was used to develop a small-animal mod

264 tumor cell-selective killing activity of the adenovirus type 2 early region 4 ORF4 (E4orf4) protein i

265 gp120 fused to the adenovirus type 2 fiber binding domain (gp120-Ad2F), a m

266 xamined.METHODSThe novel 2-dose heterologous Adenovirus type 26.ZEBOV (Ad26.ZEBOV) and modified vacci

267 me-boost regimen with recombinant chimpanzee adenovirus type 3 vectored Ebola Zaire vaccine (ChAd3-EB

268 with the Ebola vaccine candidate chimpanzee adenovirus type 3-vectored Ebola Zaire vaccine (ChAd3-EB

269 ZIKV vaccine using a low-seroprevalent human Adenovirus type 4 (Ad4-prM-E) and compared it to an Ad5

270 that gap junctions would be targeted during adenovirus type 5 (Ad5) infection.

271 ara (MVA), vesicular stomatitis virus (VSV), adenovirus type 5 (Ad5), rhesus monkey rhadinovirus (RRV

272 us purification material selective for human adenovirus type 5 (AdV5) offered highly purified virus f

273 cells due to the low infection efficiency of adenovirus type 5 for B cells.

274 d twice mucosally with replication-competent adenovirus type 5 host range mutant (Ad5hr)-simian immun

275 were mucosally primed twice with replicating adenovirus type 5 host range mutant (Ad5hr)-SIV recombin

276 rols and the microbicide-only group received adenovirus type 5 host range mutant empty vector and alu

277 were primed twice mucosally with replicating adenovirus type 5 host range mutant SIV env/rev, gag, an

278 nding site in hexon; and noninfectious human adenovirus type 5 particles assembled in the absence of

279 study, we designed a replication-incompetent adenovirus type 5 to deliver a LANA-specific Cas9 system

280 A respiratory outbreak associated with human adenovirus type 7 (HAdV-7) occurred among unvaccinated o

281 Adenovirus type 7 DNA was detected in the fifth case.

282 ting with an HLH-like illness after onset of adenovirus type 7 infection.

283 The studies detailed here indicate that adenovirus utilizes ATR kinase and CDKs during infection

284 -animal model for oral replication-competent adenovirus vaccines.

285 Single-dose vaccination with a recombinant adenovirus vector expressing hepacivirus non-structural

286 The use of an adenovirus vector might confer potential in vivo applica

287 ecific immune profiles elicited by different Adenovirus vector types and emphasize the importance of

288 A simian adenovirus vector vaccine strategy is effective at induc

289 Here we show that the adenovirus-vector-based vaccine ChAdOx1 nCoV-19, which e

290 In our previous work, we developed an Adenovirus vectored ZIKV vaccine using a low-seroprevale

291 n five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing

292 ated the protective activity of a chimpanzee adenovirus-vectored vaccine encoding a prefusion stabili

293 l therapeutic delivery of a novel chimpanzee adenovirus-vectored vaccine expressing Ag85A (AdCh68Ag85

294 ted the immunogenicity of a novel chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19 (AZD1222),

295 Vaccines based on replication-deficient adenovirus vectors either alone or in combination with a

296 Different adenovirus vectors either expressing TRAM alone or co-ex

297 Adenovirus viremia was defined as >=2 consecutive viral

298 Adenovirus Virus-Associated (VA) RNAs are the first disc

299 Between December 2014 and August 2018, adenoviruses were detected in 18.8% (629/3,347) of cases

300 dies, co-administration of a TRAM expressing adenovirus with a vaccine expressing the ME-TRAP malaria